nach oben

Diabetologia

Erschienen in:

23.08.2017 | Commentary

Should we screen for type 2 diabetes among asymptomatic individuals? Yes

verfasst von: David Simmons, Janice C. Zgibor

Erschienen in: Diabetologia | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

RCTs of whether screening asymptomatic individuals for undiagnosed diabetes results in reduced mortality or has other benefits have been suggestive, but inconclusive. In this issue of Diabetologia, two additional controlled studies (DOIs: 10.1007/s00125-017-4323-2 and 10.1007/s00125-017-4299-y) that investigated whether screening for type 2 diabetes in asymptomatic individuals is associated with a reduction in mortality are presented. Treating diabetes early, and identifying and treating impaired glucose tolerance, are of benefit, and economic modelling indicates such screening is cost-effective. Now that such screening is already underway in many countries, new data, along with the existing evidence, suggests opportunistic screening is the best way forward. More research is needed, however, on how best to screen and how to improve risk-factor control once dysglycaemia is detected.

Andermann A (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86:317–319CrossRefPubMedPubMedCentral

Eborall HC, Griffin SJ, Prevost AT et al (2007) Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 335:486CrossRefPubMedPubMedCentral

Dall TM, Narayan KMV, Gillespie KB et al (2014) Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines. Popul Health Metrics 12:12CrossRef

Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748CrossRefPubMedPubMedCentral

Simmons RK, Rahman M, Jakes RW et al (2011) Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia 54:312–319CrossRefPubMed

Rahman M, Simmons RK, Hennings SH et al (2012) How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia 55:1651–1659CrossRefPubMed

Simmons RK, Griffin SJ, Witte DR et al (2017) Effect of population screening for type 2 diabetes and cardiovasular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia doi:10.1007/s00125-017-4323-2

Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A (2017) Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia doi:10.1007/s00125-017-4299-y

Feldman AL, Griffin SJ, Fhärm E et al (2017) Screening for type 2 diabetes: do screen-detected cases fare better? Diabetologia doi:10.1007/s00125-017-4402-4

10.

Pringle M, Stewart-Evans C, Coupland C, Williams I, Allison S, Sterland J (1993) Influences on control in diabetes mellitus: patient, doctor, practice, or delivery of care? BMJ 306:630–634CrossRefPubMedPubMedCentral

11.

Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167CrossRefPubMedPubMedCentral

12.

OECD (2015) Health at a Glance 2015: OECD Indicators, OECD Publishing, Paris, pp134–135. Available from http://dx.doi.org/10.1787/health_glance-2015-en. Accessed 3 July 2017

13.

Simmons D, Yu D, Bunn C, Cohn S, Wenzel H, Prevost T (2015) Hospitalization among patients with diabetes associated with a diabetes impact initiative: a mixed methods case study. Future Hospital J 2:92–98

14.

Holman RR, Paul SK, Bethel MA et al (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589CrossRefPubMed

15.

The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMedCentral

16.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed

17.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322CrossRefPubMedPubMedCentral

18.

Diabetes Prevention Research Group (2016) Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes study. Lancet Diabetes Endocrinol 3:866–875

19.

Echouffo-Tcheugui JB, Prorok PC (2014) Considerations in the design of randomized trials to screen for type 2 diabetes. Clin Trials 11:284–291CrossRefPubMed

20.

National Institute for Health and Care Excellence (NICE) guidelines (2015). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period (NG3). Available from www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-of-diabetes-and-its-complications-from-preconception-to-the-postnatal-period-51038446021. Accessed 1 April 2015

21.

Nankervis A, McIntyre HD, Moses R, et al (2014) ADIPS consensus guidelines for the testing and diagnosis of hyperglycaemia in pregnancy in Australia and New Zealand. Available from http://adips.org/downloads/2014ADIPSGDMGuidelinesV18.11.2014_000.pdf. Accessed 2 Jan 2017

22.

Public Health England (2015) Diabetes prevalence estimates for local populations. Available from www.gov.uk/government/publications/diabetes-prevalence-estimates-for-local-populations. Accessed 15 June 2017

23.

Church D, Simmons D (2014) More evidence of the problems of using HbA1c for diagnosing diabetes? The known knowns, the known unknowns and the unknown unknowns. J Intern Med 276:171–173CrossRefPubMed

24.

Waugh NR, Shyangdan D, Taylor-Phillips S, Suri G, Hall B (2013) Screening for type 2 diabetes: a short report for the National Screening Committee. Health Technol Assess 17:1–90PubMedPubMedCentral

25.

Brown CA, Lilford RJ (2006) The stepped wedge trial design: a systematic review. BMC Med Res Methodol 6:54CrossRefPubMedPubMedCentral

26.

Engelgau MM, Narayan KM, Herman WH (2000) Screening for type 2 diabetes. Diabetes Care 23:1563–1580CrossRefPubMed

Titel: Should we screen for type 2 diabetes among asymptomatic individuals? Yes
verfasst von: David Simmons
Janice C. Zgibor
Publikationsdatum: 23.08.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 11/2017
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-017-4397-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes

Relapsing/remitting type 1 diabetes

Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion

Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells

Does the evidence support population-wide screening for type 2 diabetes? No